pharmaphorum2d
Novo Nordisk leaps on new obesity drug data
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...
Yahoo Finance4d
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
"Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this ...
FiercePharma3d
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...
Seeking Alpha3d
Novo Nordisk's Ozempic gets FDA approval for kidney disease
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...
Sky4d
Ozempic maker Novo Nordisk failed to disclose more payments made to healthcare groups - watchdog
and continue to collaborate with external partners to ensure robust systems and processes are in place," Novo Nordisk said "This has enabled us to resubmit all relevant historical data to ...
Wall Street Journal3d
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...
Pharm Exec3d
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
The FDA has approved Novo Nordisk’s Ozempic (semaglutide ... According to the company, approval was based on data from the Phase IIIb FLOW trial, which demonstrated a significant risk reduction in all ...
pharmaphorum2d
Novo Nordisk sheds billions in value on obesity data
Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction of 22.7% for CagriSema versus 11.8% with ...
India TV2d
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic to lower the ... GlobalData, a prominent data and analytics business, claimed last year that the medicine could ...
AOL3d
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
(Reuters) -The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the ... The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death ...
NBC New York3d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...